Durolane vs Monovisc for Cartilage Health: Understanding Your Treatment Options
Insights

Durolane vs Monovisc for Cartilage Health: Understanding Your Treatment Options

London Cartilage Clinic

In the realm of orthopaedic medicine and specifically in the treatment of joint and cartilage issues, patients are often presented with a variety of treatment options that can sometimes be overwhelming. Two such treatments, Durolane and Monovisc, stand out for their efficacy in managing symptoms associated with osteoarthritis and other cartilage-related conditions. This article aims to demystify these options, providing clear explanations to help you understand which treatment might be best for you.

Exploring Durolane and Monovisc: What Are They?

Both Durolane and Monovisc are hyaluronic acid-based treatments used to alleviate pain in patients with joint conditions such as osteoarthritis. They work by supplementing the viscous properties of the synovial fluid in the joint, thereby improving lubrication, reducing pain, and enhancing mobility.

Durolane: Single-Injection Simplicity

Durolane is a single-injection treatment that provides relief from osteoarthritis pain for up to six months. It's known for its high concentration of hyaluronic acid, which closely mimics the body's own synovial fluid. This treatment is particularly beneficial for patients seeking a quick, minimally invasive option with lasting results.

Monovisc: High Molecular Weight Relief

Monovisc, on the other hand, is also a single-injection treatment but is distinguished by its high molecular weight. This makes it particularly effective in providing lubrication and cushioning to the joint. Monovisc can offer pain relief that lasts for several months, with the duration of effectiveness varying from person to person.

When Are They Used?

Durolane and Monovisc are used in the management of pain and mobility issues in patients with osteoarthritis, particularly when traditional non-surgical methods such as physical therapy or NSAIDs have not provided adequate relief. They are most commonly administered in knee joints but can also be used in other joints such as the hip, shoulder, and ankle.

Who Are the Candidates?

Candidates for Durolane or Monovisc injections typically include individuals experiencing moderate to severe osteoarthritis symptoms that interfere with daily activities and quality of life. Ideal candidates are those who:

  • Have not responded well to other osteoarthritis treatments.
  • Are seeking alternatives to steroid injections or surgery.
  • Wish to avoid the downtime associated with surgical options.

Understanding the Differences

While both treatments are based on hyaluronic acid, their differences lie in their formulation and molecular weight, which can influence their suitability for different patients. Durolane's single, high-concentration injection may be preferred for its convenience and long-lasting effect. In contrast, Monovisc's high molecular weight formulation might offer a better solution for those requiring more substantial joint lubrication and cushioning.

Reclaim your mobility

In conclusion, both Durolane and Monovisc offer effective relief for those suffering from joint pain due to osteoarthritis and other cartilage issues. Understanding the differences and discussing these options with your healthcare provider can help you make an informed decision tailored to your health needs and lifestyle. At the London Cartilage Clinic, we're committed to combining advanced techniques in orthopaedics, musculoskeletal medicine, and regenerative medicine to help you reclaim your mobility and improve your quality of life.   Book a Consultation

Frequently Asked Questions

  • Typically, the effects can last from six months to a year, depending on the individual's condition and activity level.
  • Common side effects include temporary injection site pain, swelling, and stiffness. Severe reactions are rare.
  • Most patients can resume their routine activities within a few days post-injection, although it's advised to avoid strenuous activities for a short period.
  • No, they provide symptomatic relief but do not cure the underlying condition.
  • The "best" treatment depends on individual patient factors, including the severity of symptoms and personal preferences.
  • A thorough evaluation by an orthopaedic specialist is essential to determine the most appropriate treatment based on your specific needs.

Next steps

Where to go from here

These routes are selected from the topic and purpose of this article. They are guidance, not a diagnosis or treatment recommendation.

Learn more

Explore hyaluronic acid injection

Read the reviewed hyaluronic acid injection pathway, including who it may help and what happens next.

Talk to the team

Book a free discovery call

A non-medical call with the team to understand services and choose the right booking route.

Legal & Medical Disclaimer

This article is written by an independent contributor and reflects their own views and experience, not necessarily those of London Cartilage Clinic. It is provided for general information and education only and does not constitute medical advice, diagnosis, or treatment.

Always seek personalised advice from a qualified healthcare professional before making decisions about your health. London Cartilage Clinic accepts no responsibility for errors, omissions, third-party content, or any loss, damage, or injury arising from reliance on this material.

If you believe this article contains inaccurate or infringing content, please contact us at [email protected].

Last reviewed: 2026For urgent medical concerns, contact your local emergency services.

London Cartilage Clinic

Latest Insights

Clinical updates, cartilage treatment guidance, and recovery-focused articles from our specialist team.

Why microfracture and ChondroFiller outcomes diverge
Cartilage Repair
Eleanor Hayes

Why microfracture and ChondroFiller outcomes diverge

Microfracture repairs with fibrocartilage that peaks at twelve months but deteriorates by year three as secondary bone changes develop beneath the repair; ChondroFiller injection sustains improvement at three years by avoiding subchondral bone disruption.

Who qualifies for ChondroFiller injection
ChondroFiller / Liquid Cartilage
Eleanor Hayes

Who qualifies for ChondroFiller injection

ChondroFiller is indicated for the full cartilage-wear spectrum—from early lesions to Grade IV (bone-on-bone) osteoarthritis—with no age limit and no defect-size ceiling; candidacy hinges on joint stability, not disease severity.

Partial ACL tears and why they go unrecognised
ACL Injury
Eleanor Hayes

Partial ACL tears and why they go unrecognised

Partial ACL tears present identically to sprains — modest swelling, returning weight-bearing comfort — but delay past six weeks eliminates the repair option, leaving reconstruction as the only surgical route.

Privacy & Cookies Policy
Free Discovery Call